Although aging is the main risk factor for the development of Alzheimer’s diseaseEmerging evidence suggests that metabolic disturbances such as diabetes type 2 They also contribute significantly to its appearance. In fact, several studies have described a Close link between Alzheimer’s and diabetes II, with clinical evidence showing that both diseases co-exist. However, the underlying mechanisms in this regard were not completely clear.
Now, a study published in CNS Fluids and Barriers in which the researchers University of Cadiz Mónica García Aloza and María Vargas Soria, together with Juan José Ramos Rodríguez, a professor in the Department of Physiology at the University of Granada, discovered that diabetes favors soluble forms of amyloid beta peptide, which are particularly toxic and damaging to neuronal tissue. Huh. … all it seems to do is facilitate the dilation of blood vessels in the brain and increase brain nerve deathtypical of Alzheimer’s disease.
process description Amyloid beta peptide deposition The combined model of Alzheimer’s disease and diabetes provides a new therapeutic target to work on to slow or stop the progression of this dementia. It is one of the main ways to explore the future.
Why prediabetes contributes to cognitive decline
In recent years, diabetes and prediabetes have been recognized as a risk factor for dementia, but the mechanisms mediating this association are not fully known. This work highlights one of the ways in which type 2 diabetes mellitus or its earlier stage, prediabetes, contribute to cognitive decline and accelerate the progression of Alzheimer’s disease. This study describes a new development of amyloid beta pathology in Alzheimer’s patients who also suffer from prediabetes or type 2 diabetes.
The novelty of the obtained results is based on the detection of a different progression of amyloid beta pathology when only Alzheimer’s disease is encountered and a second development when this dementia is accompanied by type 2 diabetes or prediabetes. In the combined model, one is Increased accumulation of amyloid beta peptide at the vascular level, which is known as beta-amyloid angiopathy. Furthermore, diabetes favors soluble forms of the amyloid beta peptide, which are the most toxic and damaging to neuronal tissue. Said modification of beta-amyloid pathology leads to increased oxidative stress at the neuronal and vascular levels. All of this facilitates the breakdown of blood vessels in the brain and exacerbates the neuronal death typical of Alzheimer’s disease.
The probe has been developed thanks to the sophisticated technology of multiphoton microscopy In a living animal, that allows the same animal and brain pathology to be monitored over time. “This reduces the number of animals needed in research,” explains UGR professor Juan José Ramos, without doubt a huge advantage over more rudimentary techniques, which triple the number of animals needed to conduct a similar study. “. ‘In vivo’ multiphoton microscopy is a technique within reach of some laboratories, capable of offering data and images that cannot be achieved with other techniques. “The next question we ask ourselves is: By controlling diabetes pathology, can we control or reduce the progression of beta-amyloid pathology and its consequences?” Researchers from the University of Granada have concluded.